facturing needs through innovation, technology and service. Specializing in semi-solid and liquid dosage forms, DPT has a reputation for quality, unmatched technical expertise, extensive manufacturing capabilities and an exemplary regulatory compliance record. With five cGMP facilities, including R&D, manufacturing and packaging operations in San Antonio, Texas, and Lakewood, New Jersey, DPT offers full service outsourcing solutions. For more information, call 210-476-8100 or visit www.DPTLabs.com
About HEALTHPOINT, Ltd.
Since 1992, HEALTHPOINT has been dedicated to innovative technologies for the prevention and treatment of acute, chronic and burn-related wounds. The company is presently focused on the research and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: Collagenase SANTYL® Ointment, OASIS® Wound Matrix and HYDROFERA BLUE® Bacteriostatic Wound Dressings. HEALTHPOINT is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. HEALTHPOINT is a DFB Pharmaceuticals, Inc. affiliate company, and is based in Fort Worth, Texas. For more information, visit the HEALTHPOINT website at www.healthpoint.com.
Healthpoint and design, SANTYL, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.
OASIS is a registered trademark of Cook Biotech, Inc.
HYDROFERA BLUE is a registered trademark of Hydrofera, LLC. Page: 1 2 Related medicine technology :1
. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm2
. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury3
. FDA Approves New Treatment Option for Late-Stage Breast Cancer4
. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents5
. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain6
. FDA Approves New Indication for Afinitor7
. FDA Approves Teflaro for Bacterial Infections8
. FDA Approves Latuda to Treat Schizophrenia in Adults9
. FDA Approves Additional Medical Indication for Sprycel10
. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation11
. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation